Article Per Year (5 Year)
p-Index From 2019 - 2024
0.23
P-Index
This Author published in this journals
All Journal Jurnal Kedokteran Diponegoro
Mohamad Mimbar Topik
Department of Dermatology & Venerology, Faculty of Medicine, RSUD Cut Meutia, Aceh Utara
Medicine & Pharmacology

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
Case Report : Chromoblastomycosis Melina Handayani; Mohamad Mimbar Topik
Jurnal Kedokteran Diponegoro (Diponegoro Medical Journal) Vol 12, No 6 (2023): JURNAL KEDOKTERAN DIPONEGORO (DIPONEGORO MEDICAL JOURNAL)
Publisher : Faculty of Medicine, Universitas Diponegoro, Semarang, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.14710/dmj.v12i6.38536

Abstract

Background: Chromoblastomycosis is a recurring deep mycosis of the skin and subcutaneous towel. Clinical features are characterized by verrucous shrine lesions, especially in the lower extremities. This disease is usually preceded by trauma in the form of a wound which is the initial implantation of the fungus. The fungus will be implanted in the dermis and will infect the skin with the subcutaneous towel. Chromoblastomycosis is caused by a fungus from the Dematiaceae family. Although Chromoblastomycosis occurs worldwide, it is most common (>70%) in tropical and subtropical regions. Case Presentation: We present a case in which a 72-year-old man came to the dermatovenereology polyclinic with the main complaint of thickening of the skin in the plantar of the right leg, the surface is rough, the skin looks dry, it doesn't itch and it doesn't hurt, it gets worse over time, widened. Based on the histopathology, the appearance of the epidermis in the form of pseudoepitheliomatous hyperplasia, hyperkeratosis, acanthosis, microabscesses with neutrophil inflammatory cells, lymphocytes, multinucleated giant cells, and spores. In the dermis, microabscesses were found, and no necrosis was seen. Conclusion: The diagnosis was chromoblastomycosis. This patient was given oral antimycotic Itraconazole 2 x 200 mg/day. There was a clinical improvement.
Co-Authors Melina Handayani